Loading stock data…
ANI Pharmaceuticals, Inc. (ANIP)
$71.23-0.76 (-1.06%)
Pre-Market$70.05-1.18 (-1.66%)· Last close Sep 4
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANI Pharmaceuticals, Inc. in the Healthcare sector is trading at $71.23 with a market capitalization of $1.7B. Wall Street consensus targets $108.38 (8 analysts), implying a +52.1% move over the next 12 months. The stock is currently near its 52-week low of $70.15, remaining 10.2% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +52.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $237.46M↓ | $247.06M↑ | $227.81M↑ | $211.37M↑ | $197.12M |
| Gross Profit | $143.88M↓ | $146.79M↑ | $134.42M↓ | $136.76M↑ | $124.08M |
| Operating Income | $38.71M↑ | $29.13M↑ | $22.83M↑ | $15.17M↑ | $14.10M |
| Net Income | $29.49M↑ | $27.49M↑ | $26.62M↑ | $8.55M↓ | $15.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.68
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.14%
Volume
Today's trading volume
219,218
Recent News
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
2 Value Stocks on Our Watchlist and 1 We Find Risky
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
2 Reasons to Like ANIP (and 1 Not So Much)
ANI Pharmaceuticals currently trades at $76.15 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock also fell short of the S&P 500’s 11.7% gain during that period.
1 Russell 2000 Stock to Target This Week and 2 We Brush Off
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call
ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the rapid scale-up of its sales force for Cortrophin Gel and robust demand across existing specialties. CEO Nikhil Lalwani noted, “We are seeing significant momentum in demand in the third quarter with July representing the highest month for new cases initiated,” attributing quarterly performance to pers